Literature DB >> 32294353

Epidemiologic and Survival Trends in Amyloidosis, 1987-2019.

Sriram Ravichandran1, Helen J Lachmann1, Ashutosh D Wechalekar1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32294353     DOI： 10.1056/NEJMc1917321

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

Review 1.  The genetics of cardiac amyloidosis.

Authors:  Scott Arno; Jennifer Cowger
Journal:  Heart Fail Rev       Date:  2021-09-13       Impact factor: 4.654

Review 2.  Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy.

Authors:  A Hänselmann; D Berliner; J Bauersachs; U Bavendiek
Journal:  Herz       Date:  2022-06-08       Impact factor: 1.740

3.  An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.

Authors:  Duncan Richards; Helen Millns; Louise Cookson; Mary Ann Lukas
Journal:  Orphanet J Rare Dis       Date:  2022-07-09       Impact factor: 4.303

4.  Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.

Authors:  Steven Law; Melanie Bezard; Aviva Petrie; Liza Chacko; Oliver C Cohen; Sriram Ravichandran; Olabisi Ogunbiyi; Mounira Kharoubi; Sashiananthan Ganeshananthan; Sharmananthan Ganeshananthan; Janet A Gilbertson; Dorota Rowczenio; Ashutosh Wechalekar; Ana Martinez-Naharro; Helen J Lachmann; Carol J Whelan; David F Hutt; Philip N Hawkins; Thibaud Damy; Marianna Fontana; Julian D Gillmore
Journal:  Eur Heart J       Date:  2022-07-14       Impact factor: 35.855

5.  Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience.

Authors:  Maaike Brons; Steven A Muller; Frans H Rutten; Manon G van der Meer; Alexander F J E Vrancken; Monique C Minnema; Annette F Baas; Folkert W Asselbergs; Marish I F J Oerlemans
Journal:  Eur Heart J Open       Date:  2022-02-24

6.  Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.

Authors:  Sriram Ravichandran; Oliver C Cohen; Steven Law; Darren Foard; Marianna Fontana; Ana Martinez-Naharro; Carol Whelan; Julian D Gillmore; Helen J Lachmann; Sajitha Sachchithanantham; Shameem Mahmood; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Blood Cancer J       Date:  2021-06-21       Impact factor: 11.037

Review 7.  Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021.

Authors:  Weijia Li; Dipan Uppal; Yu-Chiang Wang; Xiaobo Xu; Damianos G Kokkinidis; Mark I Travin; James M Tauras
Journal:  Diagnostics (Basel)       Date:  2021-05-30

Review 8.  Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.

Authors:  Mathew S Maurer; Preston Dunnmon; Mariana Fontana; Cristina Candida Quarta; Krishna Prasad; Ronald M Witteles; Claudio Rapezzi; James Signorovitch; Isabelle Lousada; Giampaolo Merlini
Journal:  Circ Heart Fail       Date:  2022-03-25       Impact factor: 10.447

9.  Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.

Authors:  Andrew Staron; Luke Zheng; Gheorghe Doros; Lawreen H Connors; Lisa M Mendelson; Tracy Joshi; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2021-08-04       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.